“Psyence Biomedical’s Phase IIb Psilocybin Breakthrough: Debt-Free, Cash‑Rich, Ready to Revolutionize Mental Health”
Discover how Psyence Biomedical’s debt‑free, $9.5 M‑cash position fuels its leap to Phase IIb psilocybin trials, positioning it as a rising force in psychedelic therapeutics.
3 minutes to read


